Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2001, p. 1244-1248, Vol. 45, No. 4
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.4.1244-1248.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Activities of the Combination of
Quinupristin-Dalfopristin with Rifampin In Vitro and in Experimental
Endocarditis Due to Staphylococcus aureus Strains with
Various Phenotypes of Resistance to
Macrolide-Lincosamide-Streptogramin Antibiotics
Virginie
Zarrouk,1
Bülent
Bozdogan,2
Roland
Leclercq,2
Louis
Garry,1
Celine
Feger,3
Claude
Carbon,1 and
Bruno
Fantin1,*
Institut National de la Santé et de la
Recherche Médicale, EMI 9933, Hôpital Bichat-Claude
Bernard, Paris,1 Service de
Microbiologie, Hôpital de la Côte de Nacre,
Caen,2 and Anti-Infective Clinical
Research, Aventis,3 France
Received 17 July 2000/Returned for modification 29 September
2000/Accepted 25 January 2001
We evaluated the activities of quinupristin-dalfopristin (Q-D),
alone or in combination with rifampin, against three strains of
Staphylococcus aureus susceptible to rifampin (MIC, 0.06 µg/ml) and to Q-D (MICs, 0.5 to 1 µg/ml) but displaying various
phenotypes of resistance to macrolide-lincosamide-streptogramin
antibiotics: S. aureus HM1054 was susceptible to
quinupristin and dalfopristin (MICs of 8 and 4 µg/ml, respectively);
for S. aureus RP13, the MIC of dalfopristin was high (MICs
of quinupristin and dalfopristin for strain RP13, 8 and 32 µg/ml,
respectively); and S. aureus HM1054R was obtained after
conjugative transfer of macrolide-lincosamide-streptogramin B
constitutive resistance to HM1054, and the MIC of quinupristin for this
strain was high (MICs of quinupristin and dalfopristin, 64 and 4 µg/ml, respectively). In vitro time-kill curve studies showed no
difference between Q-D and rifampin, at a concentration of four times
the MIC, against the three strains. Rabbits with aortic endocarditis
were treated 4 days with Q-D, rifampin, or their combination. In vivo,
the combination was highly bactericidal and synergistic against strains
susceptible to quinupristin (HM1054 and RP13) and sterilized 94% of
the animals. In contrast, the combination was neither synergistic nor
bactericidal against the quinupristin-resistant strain (HM1054R) and
did not prevent the emergence of mutants resistant to rifampin. We
conclude that the in vivo synergistic and bactericidal activity of the
combination of Q-D and rifampin against S. aureus is
predicted by the absence of resistance to quinupristin but not by in
vitro combination studies.
*
Corresponding author. Mailing address: Service de
Médecine Interne, Hôpital Beaujon, 100 avenue du
Général Leclerc, 92110 Clichy, France. Phone: 33 1 40 87 52 27. Fax: 33 1 40 87 54 95. E-mail:
bruno.fantin{at}bjn-ap-hop-paris.fr.
Antimicrobial Agents and Chemotherapy, April 2001, p. 1244-1248, Vol. 45, No. 4
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.4.1244-1248.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Muller-Serieys, C., Saleh Mghir, A., Massias, L., Fantin, B.
(2009). Bactericidal Activity of the Combination of Levofloxacin with Rifampin in Experimental Prosthetic Knee Infection in Rabbits Due to Methicillin-Susceptible Staphylococcus aureus. Antimicrob. Agents Chemother.
53: 2145-2148
[Abstract]
[Full Text]
-
Perlroth, J., Kuo, M., Tan, J., Bayer, A. S., Miller, L. G.
(2008). Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections: A Systematic Review of the Literature. Arch Intern Med
168: 805-819
[Abstract]
[Full Text]
-
Rouzet, F., Hernandez, M. D., Hervatin, F., Sarda-Mantel, L., Lefort, A., Duval, X., Louedec, L., Fantin, B., Le Guludec, D., Michel, J.-B.
(2008). Technetium 99m-Labeled Annexin V Scintigraphy of Platelet Activation in Vegetations of Experimental Endocarditis. Circulation
117: 781-789
[Abstract]
[Full Text]
-
Goldstein, F.
(2007). The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother
59: 1-4
[Abstract]
[Full Text]
-
Murphy, C. K., Mullin, S., Osburne, M. S., van Duzer, J., Siedlecki, J., Yu, X., Kerstein, K., Cynamon, M., Rothstein, D. M.
(2006). In Vitro Activity of Novel Rifamycins against Rifamycin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother.
50: 827-834
[Abstract]
[Full Text]
-
Giacometti, A., Cirioni, O., Ghiselli, R., Orlando, F., Mocchegiani, F., Riva, A., Del Prete, M. S., Saba, V., Scalise, G.
(2002). Efficacy of Quinupristin-Dalfopristin in Preventing Vascular Graft Infection Due to Staphylococcus epidermidis with Intermediate Resistance to Glycopeptides. Antimicrob. Agents Chemother.
46: 2885-2888
[Abstract]
[Full Text]
-
Pavie, J., Lefort, A., Zarrouk, V., Chau, F., Garry, L., Leclercq, R., Fantin, B.
(2002). Efficacies of Quinupristin-Dalfopristin Combined with Vancomycin In Vitro and in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus in Relation to Cross-Resistance to Macrolides, Lincosamides, and Streptogramin B- Type Antibiotics. Antimicrob. Agents Chemother.
46: 3061-3064
[Abstract]
[Full Text]
-
Batard, E., Jacqueline, C., Boutoille, D., Hamel, A., Drugeon, H. B., Asseray, N., Leclercq, R., Caillon, J., Potel, G., Bugnon, D.
(2002). Combination of Quinupristin-Dalfopristin and Gentamicin against Methicillin-Resistant Staphylococcus aureus: Experimental Rabbit Endocarditis Study. Antimicrob. Agents Chemother.
46: 2174-2178
[Abstract]
[Full Text]
-
Saleh-Mghir, A., Ameur, N., Muller-Serieys, C., Ismael, F., Lemaitre, F., Massias, L., Feger, C., Bleton, R., Cremieux, A.-C.
(2002). Combination of Quinupristin-Dalfopristin (Synercid) and Rifampin Is Highly Synergistic in Experimental Staphylococcus aureus Joint Prosthesis Infection. Antimicrob. Agents Chemother.
46: 1122-1124
[Abstract]
[Full Text]